Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG35231

ATF4 Knockout A2780 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Ovary

  • Disease:

    Endometrioid carcinoma

The ATF4 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human ovarian carcinoma A2780 cell line, enabling loss-of-function studies of the ATF4 transcription factor. ATF4 is a central mediator of the integrated stress response, activated by kinases like PERK and GCN2, and it transcriptionally regulates targets such as CHOP and GADD34 to control adaptation to ER stress and amino acid deprivation. This model is tailored for investigating ATF4-dependent pathways in ovarian cancer, including stress-induced survival, autophagy, and chemoresistance. Typical applications encompass western blotting, RT-qPCR, tunicamycin-induced ER stress assays, and cisplatin sensitivity testing.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    A2780

    Sex of Donor

    Female

    Age

    Unknown

    Derived From Site

    In situ; Ovary

    Gene Name

    ATF4

    Gene Identifier

    NCBI Gene ID 468

    Morphology

    Epithelial-like

    Growth Mode

    Adherent and suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    DMEM

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The ATF4 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human ovarian carcinoma cell line A2780, designed to disrupt the ATF4 gene. This polyclonal product provides a heterogeneous pool of cells carrying diverse loss-of-function alleles, enabling the study of conserved ATF4-dependent signaling events without clonal selection artifacts. The population is well-suited for experiments requiring robust genetic perturbation of the integrated stress response pathway.

A2780 is an epithelial ovarian cancer cell line established from an endometrioid adenocarcinoma, widely used as a model for high-grade serous carcinoma. A2780 cells retain sensitivity to platinum-based agents and activate cytoprotective stress pathways, making them an ideal host for investigating ATF4’s role in tumor cell survival and chemoresistance. The polyclonal knockout in this background allows examination of ATF4 functions within a clinically relevant ovarian cancer context.

ATF4 functions as a master transcription factor of the integrated stress response (ISR), activated downstream of eIF2?? phosphorylation by kinases including EIF2AK3 (PERK), EIF2AK4 (GCN2), EIF2AK2 (PKR), and EIF2AK1 (HRI) during ER stress, amino acid deprivation, and oxidative stress. Upon translation, ATF4 induces expression of target genes such as DDIT3 (CHOP), ATF3, PPP1R15A (GADD34), ASNS, SLC7A11, VEGFA, BCL2, and PMAIP1 (NOXA), thereby regulating amino acid metabolism, redox homeostasis, autophagy, and apoptosis. ATF4 also associates with transcriptional partners including CREBBP/EP300 (CBP/p300), CHOP, ATF3, and JUN to integrate upstream signals from mTORC1 and hypoxia. This network positions ATF4 as a central mediator of adaptive and apoptotic responses.

In ovarian carcinoma, ATF4-driven ISR contributes to cisplatin resistance by promoting pro-survival genes and modulating autophagic and apoptotic pathways. The A2780 ATF4 knockout polyclonal cells enable detailed dissection of how ATF4 loss alters sensitivity to ER stress inducers like tunicamycin, affects cell viability under nutrient deprivation, and reshapes downstream gene expression. This model is particularly valuable for exploring feedback mechanisms via GADD34-mediated eIF2?? dephosphorylation and for identifying ATF4-dependent vulnerabilities that could be exploited therapeutically.

Researchers can utilize this polyclonal knockout product for western blotting and RT-qPCR analyses of ATF4, phospho-eIF2??, CHOP, and ATF3; tunicamycin- or amino acid starvation-induced ISR assays; cell viability and apoptosis quantification under stress; and cisplatin dose-response curves to assess chemoresistance. Additional applications include immunofluorescence for ATF4 nuclear translocation, RNA-seq transcriptomic profiling to map ATF4 regulons, and phospho-eIF2?? flow cytometry to monitor ISR activation kinetics. For further technical details, please contact our support team.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)